breast cancer

[Context Therapeutics, Inc. (BioSpace, Inc.)] Context Therapeutics, Inc. announced the first patient has been dosed in the Phase II Trial of Onapristone in combination with Fulvestrant for patients with ER-positive, and HER2-negative metastatic breast cancer after progression on endocrine therapy and CDK 4/6 Inhibitors.

[Nature Cancer] The authors reported the identification of tumoral ring finger protein 2 (RNF2), the core subunit of polycomb repressor complex 1, as a negative regulator of antitumor immunity in various human cancers, including breast cancer.

[Molecular Therapy-Nucleic Acids] A type of smart exosomes was developed, in which the exosome surface was functionally engineered with CD62L and OX40L by forced expression of the genes in the donor cells.

[Cytokine] The authors investigated supportive therapy potential of acidophilus milk and propolis extract in the mouse xenograft breast cancer model.

[Cancer Cell] Investigators demonstrated that high levels of baseline CXCL13+ T cells are linked to the proinflammatory features of macrophages and can predict effective responses to the combination therapy.

[Bioengineered] Scientists reported that the combination of curdione and docetaxel (DTX) strengthened the DTX-induced pro-apoptotic effects in TNBC cells and identified its involved signaling pathways.